Citation

Hassanin H, Harbi A, Saif A, Davis J, Easa D, Harrigan R. Hawaii Med. J. 2010; 69(1): 17-19.

Affiliation

Uniformed Services University of the Health Sciences, Forest Hills, NY 11375, USA. HHassanin@aol.com

Copyright

(Copyright © 2010, Hawaii Medical Association)

DOI

unavailable

PMID

20222492

PMCID

PMC3104626

Abstract

OBJECTIVES: To study prescribing trends for antidepressants in Hawai'i following the FDA black box warning regarding the possible risk of suicide in children and adolescents. We also explored relationships between changes in prescribing trends and patient and provider characteristics. STUDY DESIGN: Analysis of an existing insurance data set of prescriptions to children and adolescents within the State of Hawai'i. STUDY POPULATION: Children and adolescents under 18-years-old insured through the largest (>60%) third-party insurance company in the state. RESULTS: Our results showed variations in changes in prescribing trends for different selective serotonin reuptake inhibitors (SSRIs) following the FDA black box warning. SSRIs with more evidence-based research supporting their safety and efficacy were least affected as were those that were less implicated by the FDA analysis of the possible link between SSRIs and Suicidality. Trends were apparent for all age groups examined and for both females and males. CONCLUSIONS: Changes in prescribing patterns of psychiatric medications for children and adolescents in Hawai'i were identified. Differing patterns have evolved since 2003 following the series of concerns raised regarding SSRIs and suicidality in children and adolescents.

Language: en